Table 2.
Patient Demographics
| Demographics | TAV (n=61) | BAV (n=74) | P Value |
|---|---|---|---|
| Age, y | 64.4±11 | 55.5±13 | <0.001 |
| Male subjects | 71% | 64.4% | 0.164 |
| Smokers | 19.4% | 43% | 0.004 |
| Diabetes mellitus | 13.2% | 5.3% | 0.312 |
| Hypertension | 43.40% | 31.6% | 0.024 |
| Coronary artery disease | 22.6% | 5.4% | 0.003 |
| Hyperlipidemia | 43.4% | 27.7% | 0.024 |
| Baseline sRAGE | 733.9±49.3 | 1765±142.9 | <0.0001 |
| Diagnosis and type of surgery | |||
| Aortic valve insufficiency | 68.9% | 70.3% | 0.351 |
| Aortic valve stenosis | 34.4% | 74.3% | 0.002 |
| Aortic valve repair/replacement | 55.73% | 43.24% | 0.025 |
| AVR and AA repair/replacement | 44.3% | 56.8% | 0.080 |
Demographic and clinical details: total n=135 surgical patients. AA indicates ascending aortic replacement; AVR, aortic valve replacement; BAV, bicuspid aortic valve; sRAGE, soluble receptor for advanced glycation end product; and TAV, tricuspid aortic valve.